menu
    • menu
    [{"orgOrder":0,"company":"Mitotech","sponsor":"Essex Bio","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Visomitin","moa":"Cardiolipin peroxidation","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Mitotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Mitotech \/ Essex Bio","highestDevelopmentStatusID":"10","companyTruncated":"Mitotech \/ Essex Bio"},{"orgOrder":0,"company":"Mitotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Visomitin","moa":"Cardiolipin peroxidation","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Mitotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Mitotech \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Mitotech \/ Not Applicable"},{"orgOrder":0,"company":"Mitotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Visomitin","moa":"Cardiolipin peroxidation","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Mitotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Mitotech \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Mitotech \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Mitotech

    Menu

    Mitotech

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Mitotech

                            Luxembourg arrow
                            2024 ACI Convention
                            Not Confirmed

                            Mitotech

                            Luxembourg arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Visomitin

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Mitotech CSO to Present at Mitochondria-Targeted Drug Development Summit

                            Details : SkQ1 (visomitin), is a cardiolipin peroxidation inhibitor, designed to sustain and restore mitochondrial function and interrupt apoptosis in mitochondrial conditions like LHON, dry eye disease and glaucoma.

                            Brand Name : SkQ1

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            February 24, 2022

                            Lead Product(s) : Visomitin

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Mitotech

                            Luxembourg arrow
                            2024 ACI Convention
                            Not Confirmed

                            Mitotech

                            Luxembourg arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Visomitin

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Mitotech Granted Orphan Drug Designation by FDA for Visomitin in LHON

                            Details : USFDA has granted ODD for the company’s topical cardiolipin peroxidation inhibitor, SkQ1(Visomitin), for the treatment of Leber’s Hereditary Optic Neuropathy a rare inherited condition that can lead to blindness.

                            Brand Name : SkQ1

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            December 15, 2021

                            Lead Product(s) : Visomitin

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Mitotech

                            Luxembourg arrow
                            2024 ACI Convention
                            Not Confirmed

                            Mitotech

                            Luxembourg arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Visomitin

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase III

                            Sponsor : Essex Bio

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Mitotech and Essex Bio-Technology Complete Enrollment in VISTA-2 – a pivotal Phase 3 Clinical Study of SkQ1 ...

                            Details : VISTA-2 is a multi-centre, randomized, double-blind, placebo-controlled clinical study involving two treatment arms: SkQ1 ophthalmic solution and vehicle solution, administered BID.

                            Brand Name : SkQ1

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            August 25, 2020

                            Lead Product(s) : Visomitin

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase III

                            Sponsor : Essex Bio

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth